Loading
Ying Cheng has led most of the Chinese small cell lung cancer immunotherapy trials, including ASTRUM-005 and CAPSTONE-1.
Principal investigator of ASTRUM-005 (serplulimab plus chemotherapy, JAMA 2022), CAPSTONE-1 (adebrelimab plus chemotherapy, Lancet Oncology 2022) and the benmelstobart plus anlotinib trial in extensive-stage SCLC, as well as Chinese cohorts of global lung cancer studies; chairs CSCO's small cell lung cancer committee.
Shares Anlotinib and the tag china.
Shares ASTRUM-005, Serplulimab, Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag china.
Shares CAPSTONE-1, Adebrelimab, Small-cell lung cancer and the tag china.
Shares Anlotinib and the tag china.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag china.
Shares Serplulimab, Limited-stage small-cell lung cancer, Adebrelimab, Extensive-stage small-cell lung cancer.
Shares Serplulimab, Limited-stage small-cell lung cancer, Small-cell lung cancer.
Shares Serplulimab, Extensive-stage small-cell lung cancer, Small-cell lung cancer.